The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function

Clinical and Experimental Nephrology

Volumn 8, Issue 3, 2004, Pages 237-242

  Moriyama, Takahito ^a   Honda, Kazuho ^a   Nitta, Kosaku ^a   Yumura, Wako ^a   Nihei, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Active glomerular lesion; IgA nephropathy; Proteinuria; Renal dysfunction; Steroid therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CREATININE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; IMMUNOGLOBULIN A; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CELL PROLIFERATION; CELL SHAPE; CREATININE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; JAPAN; KIDNEY DYSFUNCTION; MALE; MESANGIUM CELL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; STEROID THERAPY;

ADULT; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; CREATININE; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PREDNISOLONE; PROTEINURIA; STEROIDS;

EID: 7044232024     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-004-0298-7     Document Type: Article

References (24)

1. Berger J, Hinglais N. Les dépôts intercapillaires d'IgA-IgG. J Urol Nephrol 1968;74:694-5.
2. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis 1987;29:526-32.
3. Kobayashi Y, Hiki Y, Kokubo T, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-42.
4. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 1999;353:883-7.
5. Taneda S, Honda K, Nitta K, Kobayashi H, Uchida K, Yumura W, et al. Clinicopathological study of IgA nephropathy in adults: the influence of onset age on clinical and renal histological findings and on the effect of steroid therapy. Clin Exp Nephrol 1999;3:96-103.
6. Masaki T, Yorioka, Yamakido M. The influence of steroid therapy in patients with IgA nephropathy. Nephron 2000;86:197-8.
7. Honda K, Nitta K, Kobayashi H, Uchida K, Kawashima A, Horita S, et al. Clinical significance of histological grading and staging for predicting the effectiveness of steroid therapy in IgA nephropathy. Clin Exp Nephrol 2000;4:241-50.
8. Locatelli F, Pozzi C, Del Vecchio L, Bolasco PG, Fogazzi GB, Andrulli S, et al. Role of proteinuria reduction in the progression of IgA nephropathy. Renal Fail 2001;23:495-505.
9. Tamura S, Ueki K, Ideura H, Tsukada Y, Maezawa A, Kawai H, et al. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 2001;55:192-95.
10. Tomiyoshi Y, Sakemi T, Ikeda Y, Ohtsuka Y, Nakamura M, Fujisaki T. Cellular crescents and segmental glomerular necrosis in IgA nephropathy are indicative of the benefical effects of corticosteroid therapy. Intern Med 2001;40:862-6.
11. Roccatello D, Ferro M, Cesano G. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000;15:833-5.
12. McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001;56:193-8.
13. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-8.
14. Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee EJ, et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1987;27:56-64.
15. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 1999;10:1772-7.
16. Branten AJ, Klasen IS, Wetzels JF. Short-term effects of fish oil treatment on urinary excretion of high-and low-molecular weight proteins in patients with IgA nephropathy. Clin Nephrol 2002;58:267-74.
17. Coppo R, Chiesa M, Peruzzi L, Amore A. Treatment of IgA nephropathy with angiotensin converting inhibitors: design of a prospective randomized multicenter trial. J Nephrol 2001;14:447-52.
18. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000;58:2485-91.
19. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000;20:373-9.
20. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
21. Watanabe Y, Honda K, Uchida K, Nitta K, Nihei H. Therapeutic effect of angiotensin receptor antagonist on patients with IgA nephropathy. J Tokyo Worn Med Univ 2003;73:14-21.
22. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficiency of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003;63:1861-7.
23. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736-43.
24. Tomino Y. Therapeutic guideline for IgA nephropathy. Jpn J Nephrol 2002;44:673-9.